ANI Pharmaceuticals Competitors

Aurinia Pharmaceuticals (NASDAQ:AUPH) and ANI Pharmaceuticals (NASDAQ:ANIP) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, earnings, risk, dividends, analyst recommendations and profitability.

Insider & Institutional Ownership

51.2% of Aurinia Pharmaceuticals shares are owned by institutional investors. Comparatively, 53.4% of ANI Pharmaceuticals shares are owned by institutional investors. 24.8% of ANI Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Aurinia Pharmaceuticals and ANI Pharmaceuticals' revenue, earnings per share and valuation.

ANI Pharmaceuticals has higher revenue and earnings than Aurinia Pharmaceuticals. Aurinia Pharmaceuticals is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent recommendations for Aurinia Pharmaceuticals and ANI Pharmaceuticals, as provided by MarketBeat.

Aurinia Pharmaceuticals currently has a consensus target price of $28.50, suggesting a potential upside of 123.00%. ANI Pharmaceuticals has a consensus target price of $46.00, suggesting a potential upside of 36.74%. Given Aurinia Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts clearly believe Aurinia Pharmaceuticals is more favorable than ANI Pharmaceuticals.

Profitability

This table compares Aurinia Pharmaceuticals and ANI Pharmaceuticals' net margins, return on equity and return on assets.

Risk & Volatility

Aurinia Pharmaceuticals has a beta of 0.87, indicating that its stock price is 13% less volatile than the S&P 500. Comparatively, ANI Pharmaceuticals has a beta of 1.34, indicating that its stock price is 34% more volatile than the S&P 500.

Summary

ANI Pharmaceuticals beats Aurinia Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

Harmony Biosciences (NASDAQ:HRMY) and ANI Pharmaceuticals (NASDAQ:ANIP) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, risk, earnings, profitability, analyst recommendations, dividends and valuation.

Earnings and Valuation

This table compares Harmony Biosciences and ANI Pharmaceuticals' top-line revenue, earnings per share and valuation.

ANI Pharmaceuticals has higher revenue and earnings than Harmony Biosciences.

Insider and Institutional Ownership

50.2% of Harmony Biosciences shares are owned by institutional investors. Comparatively, 53.4% of ANI Pharmaceuticals shares are owned by institutional investors. 24.8% of ANI Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Harmony Biosciences and ANI Pharmaceuticals' net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of recent ratings for Harmony Biosciences and ANI Pharmaceuticals, as provided by MarketBeat.com.

Harmony Biosciences presently has a consensus target price of $51.6667, suggesting a potential upside of 77.85%. ANI Pharmaceuticals has a consensus target price of $46.00, suggesting a potential upside of 36.74%. Given Harmony Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Harmony Biosciences is more favorable than ANI Pharmaceuticals.

Summary

ANI Pharmaceuticals beats Harmony Biosciences on 5 of the 9 factors compared between the two stocks.

uniQure (NASDAQ:QURE) and ANI Pharmaceuticals (NASDAQ:ANIP) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, risk, earnings, profitability, analyst recommendations, dividends and valuation.

Earnings and Valuation

This table compares uniQure and ANI Pharmaceuticals' top-line revenue, earnings per share and valuation.

ANI Pharmaceuticals has higher revenue and earnings than uniQure. uniQure is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

uniQure has a beta of 1.19, indicating that its share price is 19% more volatile than the S&P 500. Comparatively, ANI Pharmaceuticals has a beta of 1.34, indicating that its share price is 34% more volatile than the S&P 500.

Insider and Institutional Ownership

78.3% of uniQure shares are owned by institutional investors. Comparatively, 53.4% of ANI Pharmaceuticals shares are owned by institutional investors. 2.8% of uniQure shares are owned by company insiders. Comparatively, 24.8% of ANI Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares uniQure and ANI Pharmaceuticals' net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of recent ratings for uniQure and ANI Pharmaceuticals, as provided by MarketBeat.com.

uniQure presently has a consensus target price of $68.4615, suggesting a potential upside of 95.49%. ANI Pharmaceuticals has a consensus target price of $46.00, suggesting a potential upside of 36.74%. Given uniQure's stronger consensus rating and higher probable upside, analysts plainly believe uniQure is more favorable than ANI Pharmaceuticals.

Summary

ANI Pharmaceuticals beats uniQure on 8 of the 15 factors compared between the two stocks.

ADC Therapeutics (NYSE:ADCT) and ANI Pharmaceuticals (NASDAQ:ANIP) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, risk, earnings, profitability, analyst recommendations, dividends and valuation.

Earnings and Valuation

This table compares ADC Therapeutics and ANI Pharmaceuticals' top-line revenue, earnings per share and valuation.

ANI Pharmaceuticals has higher revenue and earnings than ADC Therapeutics. ADC Therapeutics is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

40.9% of ADC Therapeutics shares are owned by institutional investors. Comparatively, 53.4% of ANI Pharmaceuticals shares are owned by institutional investors. 24.8% of ANI Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares ADC Therapeutics and ANI Pharmaceuticals' net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of recent ratings for ADC Therapeutics and ANI Pharmaceuticals, as provided by MarketBeat.com.

ADC Therapeutics presently has a consensus target price of $47.50, suggesting a potential upside of 90.23%. ANI Pharmaceuticals has a consensus target price of $46.00, suggesting a potential upside of 36.74%. Given ADC Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe ADC Therapeutics is more favorable than ANI Pharmaceuticals.

Summary

ANI Pharmaceuticals beats ADC Therapeutics on 7 of the 13 factors compared between the two stocks.

Myovant Sciences (NYSE:MYOV) and ANI Pharmaceuticals (NASDAQ:ANIP) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, risk, earnings, profitability, analyst recommendations, dividends and valuation.

Earnings and Valuation

This table compares Myovant Sciences and ANI Pharmaceuticals' top-line revenue, earnings per share and valuation.

ANI Pharmaceuticals has higher revenue and earnings than Myovant Sciences. Myovant Sciences is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Myovant Sciences has a beta of 2.99, indicating that its share price is 199% more volatile than the S&P 500. Comparatively, ANI Pharmaceuticals has a beta of 1.34, indicating that its share price is 34% more volatile than the S&P 500.

Insider and Institutional Ownership

33.8% of Myovant Sciences shares are owned by institutional investors. Comparatively, 53.4% of ANI Pharmaceuticals shares are owned by institutional investors. 3.9% of Myovant Sciences shares are owned by company insiders. Comparatively, 24.8% of ANI Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Myovant Sciences and ANI Pharmaceuticals' net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of recent ratings for Myovant Sciences and ANI Pharmaceuticals, as provided by MarketBeat.com.

Myovant Sciences presently has a consensus target price of $31.1667, suggesting a potential upside of 74.60%. ANI Pharmaceuticals has a consensus target price of $46.00, suggesting a potential upside of 36.74%. Given Myovant Sciences' higher probable upside, analysts plainly believe Myovant Sciences is more favorable than ANI Pharmaceuticals.

Summary

ANI Pharmaceuticals beats Myovant Sciences on 8 of the 13 factors compared between the two stocks.

Heron Therapeutics (NASDAQ:HRTX) and ANI Pharmaceuticals (NASDAQ:ANIP) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, risk, earnings, profitability, analyst recommendations, dividends and valuation.

Profitability

This table compares Heron Therapeutics and ANI Pharmaceuticals' net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of recent ratings for Heron Therapeutics and ANI Pharmaceuticals, as provided by MarketBeat.com.

Heron Therapeutics presently has a consensus target price of $29.60, suggesting a potential upside of 70.41%. ANI Pharmaceuticals has a consensus target price of $46.00, suggesting a potential upside of 36.74%. Given Heron Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Heron Therapeutics is more favorable than ANI Pharmaceuticals.

Volatility & Risk

Heron Therapeutics has a beta of 1.52, indicating that its share price is 52% more volatile than the S&P 500. Comparatively, ANI Pharmaceuticals has a beta of 1.34, indicating that its share price is 34% more volatile than the S&P 500.

Insider and Institutional Ownership

99.0% of Heron Therapeutics shares are owned by institutional investors. Comparatively, 53.4% of ANI Pharmaceuticals shares are owned by institutional investors. 12.9% of Heron Therapeutics shares are owned by company insiders. Comparatively, 24.8% of ANI Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Heron Therapeutics and ANI Pharmaceuticals' top-line revenue, earnings per share and valuation.

ANI Pharmaceuticals has higher revenue and earnings than Heron Therapeutics. Heron Therapeutics is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.